NO20006319L - Terapeutiske biarylderivater - Google Patents

Terapeutiske biarylderivater

Info

Publication number
NO20006319L
NO20006319L NO20006319A NO20006319A NO20006319L NO 20006319 L NO20006319 L NO 20006319L NO 20006319 A NO20006319 A NO 20006319A NO 20006319 A NO20006319 A NO 20006319A NO 20006319 L NO20006319 L NO 20006319L
Authority
NO
Norway
Prior art keywords
biaryl derivatives
therapeutic
therapeutic biaryl
derivatives
biaryl
Prior art date
Application number
NO20006319A
Other languages
English (en)
Other versions
NO20006319D0 (no
NO318782B1 (no
Inventor
Kelly Horne Donaldson
Barry George Shearer
David Edward Uehling
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20006319D0 publication Critical patent/NO20006319D0/no
Publication of NO20006319L publication Critical patent/NO20006319L/no
Publication of NO318782B1 publication Critical patent/NO318782B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
NO20006319A 1998-06-13 2000-12-12 Terapeutiske biarylderivate, samt fremgangsmate for fremstilling og anvendelse derav og farmasoytisk preparat NO318782B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812709.5A GB9812709D0 (en) 1998-06-13 1998-06-13 Chemical compounds
PCT/EP1999/003958 WO1999065877A1 (en) 1998-06-13 1999-06-09 Therapeutic biaryl derivatives

Publications (3)

Publication Number Publication Date
NO20006319D0 NO20006319D0 (no) 2000-12-12
NO20006319L true NO20006319L (no) 2001-02-09
NO318782B1 NO318782B1 (no) 2005-05-09

Family

ID=10833658

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006319A NO318782B1 (no) 1998-06-13 2000-12-12 Terapeutiske biarylderivate, samt fremgangsmate for fremstilling og anvendelse derav og farmasoytisk preparat

Country Status (38)

Country Link
US (1) US6251925B1 (no)
EP (1) EP1087943B1 (no)
JP (1) JP3471754B2 (no)
KR (1) KR100415877B1 (no)
CN (1) CN1214008C (no)
AP (1) AP1687A (no)
AR (1) AR029301A1 (no)
AT (1) ATE302189T1 (no)
AU (1) AU753004B2 (no)
BR (1) BR9911182B1 (no)
CA (1) CA2334713C (no)
CO (1) CO5060482A1 (no)
CZ (1) CZ299172B6 (no)
DE (1) DE69926752T2 (no)
DK (1) DK1087943T3 (no)
EA (1) EA003641B1 (no)
EE (1) EE04435B1 (no)
EG (1) EG23856A (no)
ES (1) ES2245107T3 (no)
GB (1) GB9812709D0 (no)
HK (1) HK1034253A1 (no)
HR (1) HRP20000854B1 (no)
HU (1) HUP0102668A3 (no)
ID (1) ID27841A (no)
IL (2) IL140219A0 (no)
IS (1) IS2277B (no)
MY (1) MY119542A (no)
NO (1) NO318782B1 (no)
NZ (1) NZ508805A (no)
PE (1) PE20000726A1 (no)
PL (1) PL196943B1 (no)
RS (1) RS49921B (no)
SI (1) SI1087943T1 (no)
SK (1) SK286256B6 (no)
TR (1) TR200100299T2 (no)
TW (1) TWI244471B (no)
WO (1) WO1999065877A1 (no)
ZA (1) ZA200007417B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929118D0 (en) * 1999-12-10 2000-02-02 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) * 1999-12-11 2000-02-02 Glaxo Group Ltd Process
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
CZ20031012A3 (en) 2000-10-20 2004-04-14 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
GB0102407D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
CA2459454A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
AU2003248352A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS
WO2003072571A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Salt of a pyridyl ethanolamine derivative and its use as a beta-3-adrenergic receptor agonist
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
KR100645412B1 (ko) * 2002-07-17 2006-11-15 레크 파마슈티칼스 디.디. 콜레스테롤 생합성 억제제로서의 신규한 피리딜에탄올(페닐에틸)아민 유도체, 그의 제조 방법 및 그를 함유하는제약 조성물
GB0220730D0 (en) * 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
US8030336B2 (en) * 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
CN100418944C (zh) * 2003-02-14 2008-09-17 橘生药品工业株式会社 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用
ATE399755T1 (de) 2003-02-14 2008-07-15 Kissei Pharmaceutical Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon
US7417169B2 (en) 2003-10-24 2008-08-26 Kissei Pharmaceutical Co., Ltd. Amino alcohol derivatives, medicinal composition containing the same, and use of these
EP1697301A2 (en) 2003-12-23 2006-09-06 Astellas Pharma Inc. Aminoalcohol derivatives
US7915309B2 (en) * 2007-06-20 2011-03-29 Protia, Llc Deuterium-enriched oseltamivir
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
EP2600859A1 (en) 2010-08-03 2013-06-12 Altherx Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AR089957A1 (es) 2012-02-09 2014-10-01 Altherx Inc Combinaciones farmaceuticas, combinaciones sinergicas
US9784726B2 (en) 2013-01-08 2017-10-10 Atrogi Ab Screening method, a kit, a method of treatment and a compound for use in a method of treatment
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
ES2967863T3 (es) * 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
GB8519154D0 (en) * 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
WO1995033724A1 (en) * 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists

Also Published As

Publication number Publication date
CN1214008C (zh) 2005-08-10
AR029301A1 (es) 2003-06-25
ID27841A (id) 2001-04-26
NZ508805A (en) 2003-08-29
ES2245107T3 (es) 2005-12-16
EE200000744A (et) 2002-04-15
SI1087943T1 (sl) 2005-12-31
SK19082000A3 (sk) 2001-09-11
US6251925B1 (en) 2001-06-26
HRP20000854A2 (en) 2001-12-31
DK1087943T3 (da) 2005-12-12
EG23856A (en) 2007-11-11
JP3471754B2 (ja) 2003-12-02
BR9911182B1 (pt) 2010-09-08
EP1087943A1 (en) 2001-04-04
BR9911182A (pt) 2001-03-13
PL196943B1 (pl) 2008-02-29
CA2334713A1 (en) 1999-12-23
HUP0102668A2 (hu) 2001-12-28
DE69926752T2 (de) 2006-02-02
CZ299172B6 (cs) 2008-05-07
RS49921B (sr) 2008-09-29
ATE302189T1 (de) 2005-09-15
AP2001002028A0 (en) 2001-03-31
CZ20004648A3 (en) 2001-06-13
HUP0102668A3 (en) 2002-11-28
IL140219A (en) 2006-07-05
EE04435B1 (et) 2005-02-15
TWI244471B (en) 2005-12-01
CO5060482A1 (es) 2001-07-30
DE69926752D1 (de) 2005-09-22
AU4510399A (en) 2000-01-05
AU753004B2 (en) 2002-10-03
TR200100299T2 (tr) 2001-06-21
AP1687A (en) 2006-12-04
NO20006319D0 (no) 2000-12-12
KR100415877B1 (ko) 2004-01-24
CN1312800A (zh) 2001-09-12
PE20000726A1 (es) 2000-08-24
SK286256B6 (sk) 2008-06-06
CA2334713C (en) 2006-01-17
NO318782B1 (no) 2005-05-09
IS2277B (is) 2007-09-15
IS5760A (is) 2000-12-08
YU79200A (sh) 2003-01-31
WO1999065877A1 (en) 1999-12-23
JP2002518374A (ja) 2002-06-25
EA200001172A1 (ru) 2001-08-27
HK1034253A1 (en) 2001-10-19
PL344865A1 (en) 2001-11-19
MY119542A (en) 2005-06-30
EA003641B1 (ru) 2003-08-28
EP1087943B1 (en) 2005-08-17
KR20010052791A (ko) 2001-06-25
GB9812709D0 (en) 1998-08-12
ZA200007417B (en) 2001-12-12
HRP20000854B1 (en) 2006-05-31
IL140219A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
DK1087943T3 (da) Terapeutiske biarylderivater
ATE260243T1 (de) N-aroylphenylalaninderivate
ATE235220T1 (de) Resorcinderivate
ID22781A (id) Turunan-turunan nikotinamida
DE69817186D1 (de) Diaminorhodamin-derivate
NO20010193D0 (no) Tiobenzimidazol-derivater
DK0930302T3 (da) Benzosulfonderivater
NO20010514L (no) Aminometylkarboksylsyre-derivater
ATE259810T1 (de) Phenyl-xanthinderivate
DE69841086D1 (de) 5-Deoxy-Cytidin-Derivate
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
ATE233253T1 (de) Chromanderivate
DE69829682D1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin-derivate
DE69828780D1 (de) Amidinocamptpthecin-derivate
NO981495D0 (no) Phenoxymetylpiperidin-derivater
DK1060183T3 (da) 5-deoxycytidinderivater
DK0966437T3 (da) 5-Aroylnaphthalenderivater
DK1015447T3 (da) Piperidinylmethyloxazolidinonderivat
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate
SE9802023D0 (sv) New therapeutic use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees